
Opinion|Videos|May 5, 2026
Depth and Durability of Response to Zongertinib in HER2-Positive NSCLC
Author(s)Joshua K. Sabari, MD
Zongertinib shows 77% frontline responses and 96% disease control, with rapid onset and promising durability versus other HER2 TKIs.
Advertisement
Episodes in this series

Joshua K. Sabari, MD, discusses the depth and durability of response to zongertinib in patients with HER2 mutation–positive non–small cell lung cancer, as observed in the Beamion LUNG‑1 trial. He then compares these outcomes, along with safety outcomes, with results for other agents in this setting.
Advertisement
Related to this article

The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.

During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.

The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
2
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
3
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
4
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
5

